Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adaptimmune Therapeutics plc ADAP

Healthcare Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include... see more

Recent & Breaking News (NDAQ:ADAP)

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Newsfile January 31, 2024

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Newsfile January 4, 2024

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Newsfile December 6, 2023

Adaptimmune Receives Transfer of IND for Lete-cel Program

Newsfile November 29, 2023

Adaptimmune Reports Third Quarter Financial Results and Business Update

Newsfile November 8, 2023

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Newsfile November 8, 2023

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Newsfile October 31, 2023

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Newsfile October 31, 2023

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Newsfile October 25, 2023

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Newsfile October 23, 2023

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

Newsfile September 11, 2023

Adaptimmune Reports Second Quarter Financial Results and Business Update

Newsfile August 9, 2023

Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

Newsfile August 3, 2023

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

Newsfile June 1, 2023

Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO

Newsfile May 25, 2023

Adaptimmune Reports First Quarter Financial Results and Business Update

Newsfile May 12, 2023

Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023

Newsfile April 28, 2023

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR

PR Newswire April 11, 2023

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

Newsfile April 11, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR

PR Newswire April 6, 2023